Michael Vi/iStock Editorial via Getty Images Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) is actively working with its partners to enhance laboratory testing capacity worldwide to combat the mpox outbreak. Mpox is a viral infection that causes flu-like symptoms and lesions, and WHO designated the current outbreak in Africa as a public health emergency of international concern last week. Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) said today that it is supporting the international response to the global emergency with its diagnostic tests developed for mpox.
“Our commitment to support the global response to mpox began in 2022 when we developed a suite of tests to enable global access to rapid and high-quality PCR testing,” said Matt Sause, CEO of Roche Diagnostics. Globally, the Swiss pharmaceutical company is partnering with governments, healthcare providers and organizations dedicated to combating the mpox outbreak. The drugmaker confirmed that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants.
More on Roche Holding AG, Roche Holding, etc. Roche: A Long-Term Bottom May Have Been Struck (Technical Analysis) Roche Holding AG 2024 Q2 - Results - Earnings Call Presentation Roche Holding AG (RHHBY) Q2 2024 Earnings Call Transcript J&J, Roche come out on top in S&P ratings of strongest pharma companies Roche evaluating selling cancer startup Flatiron Health - FT.
